A Potent Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine Resistant Bladder Cancer.
Development of resistance to gemcitabine is a major concern in bladder cancer therapy, and the mechanism remains unclear. Eg5 has been recently identified as an attractive target in cancer chemotherapy, so novel targeted chemotherapy with Eg5 inhibitor is expected to improve the anticancer effect in...
Saved in:
| Main Authors: | Liang Sun, Jiaju Lu, Zhihong Niu, Kejia Ding, Dongbin Bi, Shuai Liu, Jiamei Li, Fei Wu, Hui Zhang, Zuohui Zhao, Sentai Ding |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0144484&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immune checkpoint inhibitor therapy as a neoadjuvant treatment for muscle-invasive bladder carcinoma: A narrative review
by: Sentai Ding, et al.
Published: (2025-01-01) -
Clinical significance of HER2 in urothelial carcinoma and analysis of its correlation with glycolytic metabolic characteristics
by: Andong Guo, et al.
Published: (2024-12-01) -
Hinokiflavone is a novel CK2 inhibitor promoting apoptosis and synergizing with chemotherapeutic agents in cisplatin resistant bladder cancer cells
by: Tsung-Han Hsieh, et al.
Published: (2025-07-01) -
Chemotherapeutic dihydromyricetin with remarkable anti-tumor activity and biosafety for muscle invasive bladder cancer
by: Zicheng Guo, et al.
Published: (2025-07-01) -
70 YEARS E.G. NOVIKOVA
by: article Editorial
Published: (2021-08-01)